pharma · Multiple Myeloma · generalized myasthenia gravis · RNAC
Cartesian Therapeutics
Cartesian Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker RNAC. Primary therapeutic focus areas include Multiple Myeloma, generalized myasthenia gravis, Myasthaenia G
Company details
- Status
- Public
- HQ
- 7495 New Horizon Way, Frederick, Maryland 21703, US
- Founded
- 2016
- Employees
- 89
- Programs
- 12
- Drugs
- 4
- Patents
- 4
Descartes-25
Phase 1 · small molecule · Multiple Myeloma
Descartes-25 for Multiple Myeloma is a Phase 1 program (small_molecule) at Cartesian Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code DC25-1A
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cartesian Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Multiple Myeloma
- Status
- terminated
- Trials
- 1